{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T16:22:46Z","timestamp":1780590166113,"version":"3.54.1"},"reference-count":29,"publisher":"American Association for Cancer Research (AACR)","issue":"11","license":[{"start":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T00:00:00Z","timestamp":1667347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11,2]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To assess the preclinical efficacy, clinical safety and efficacy, and MTD of palbociclib plus nab-paclitaxel in patients with advanced pancreatic ductal adenocarcinoma (PDAC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Experimental Design:<\/jats:title>\n                    <jats:p>Preclinical activity was tested in patient-derived xenograft (PDX) models of PDAC. In the open-label, phase I clinical study, the dose-escalation cohort received oral palbociclib initially at 75 mg\/day (range, 50\u2012125 mg\/day; modified 3+3 design; 3\/1 schedule); intravenous nab-paclitaxel was administered weekly for 3 weeks\/28-day cycle at 100\u2012125 mg\/m2. The modified dose\u2013regimen cohorts received palbociclib 75 mg\/day (3\/1 schedule or continuously) plus nab-paclitaxel (biweekly 125 or 100 mg\/m2, respectively). The prespecified efficacy threshold was 12-month survival probability of \u226565% at the MTD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Palbociclib plus nab-paclitaxel was more effective than gemcitabine plus nab-paclitaxel in three of four PDX models tested; the combination was not inferior to paclitaxel plus gemcitabine. In the clinical trial, 76 patients (80% received prior treatment for advanced disease) were enrolled. Four dose-limiting toxicities were observed [mucositis (n = 1), neutropenia (n = 2), febrile neutropenia (n = 1)]. The MTD was palbociclib 100 mg for 21 of every 28 days and nab-paclitaxel 125 mg\/m2 weekly for 3 weeks in a 28-day cycle. Among all patients, the most common all-causality any-grade adverse events were neutropenia (76.3%), asthenia\/fatigue (52.6%), nausea (42.1%), and anemia (40.8%). At the MTD (n = 27), the 12-month survival probability was 50% (95% confidence interval, 29.9\u201367.2).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This study showed the tolerability and antitumor activity of palbociclib plus nab-paclitaxel treatment in patients with PDAC; however, the prespecified efficacy threshold was not met.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration:<\/jats:title>\n                    <jats:p>Pfizer Inc (NCT02501902)<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>In this article, the combination of palbociclib, a CDK4\/6 inhibitor, and nab-paclitaxel in advanced pancreatic cancer evaluates an important drug combination using translational science. In addition, the work presented combines preclinical and clinical data along with pharmacokinetic and pharmacodynamic assessments to find alternative treatments for this patient population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-22-0072","type":"journal-article","created":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T10:02:15Z","timestamp":1663322535000},"page":"1326-1333","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A Preclinical and Phase Ib Study of Palbociclib plus Nab-Paclitaxel in Patients with Metastatic Adenocarcinoma of the Pancreas"],"prefix":"10.1158","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3765-3318","authenticated-orcid":true,"given":"Manuel","family":"Hidalgo","sequence":"first","affiliation":[{"name":"1Hematology and Medical Oncology, Weill Cornell Medicine, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3342-397X","authenticated-orcid":true,"given":"Rocio","family":"Garcia-Carbonero","sequence":"additional","affiliation":[{"name":"2Oncology Department, Hospital Universitario 12 de Octubre, Imas12, UCM, CNIO, CIBERONC, Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2766-200X","authenticated-orcid":true,"given":"Kian-Huat","family":"Lim","sequence":"additional","affiliation":[{"name":"3Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wells A.","family":"Messersmith","sequence":"additional","affiliation":[{"name":"4School of Medicine, University of Colorado Cancer Center, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2273-9028","authenticated-orcid":true,"given":"Ignacio","family":"Garrido-Laguna","sequence":"additional","affiliation":[{"name":"5Department of Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5136-5462","authenticated-orcid":true,"given":"Erkut","family":"Borazanci","sequence":"additional","affiliation":[{"name":"6HonorHealth\/TGen, Scottsdale, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7106-0735","authenticated-orcid":true,"given":"Andrew M.","family":"Lowy","sequence":"additional","affiliation":[{"name":"7Department of Surgery, UC San Diego Moores Cancer Center, San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8041-3547","authenticated-orcid":true,"given":"Laura","family":"Medina Rodriguez","sequence":"additional","affiliation":[{"name":"8Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6646-0200","authenticated-orcid":true,"given":"Daniel","family":"Laheru","sequence":"additional","affiliation":[{"name":"9Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3842-2383","authenticated-orcid":true,"given":"Beatriz","family":"Salvador-Barbero","sequence":"additional","affiliation":[{"name":"10School of Biosciences, European Cancer Stem Cell Research Institute, Cardiff University, Cardiff, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0829-6315","authenticated-orcid":true,"given":"Marcos","family":"Malumbres","sequence":"additional","affiliation":[{"name":"11Cell Division and Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Shields","sequence":"additional","affiliation":[{"name":"12Centers for Therapeutic Innovation, Pfizer Inc, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2130-2783","authenticated-orcid":true,"given":"Joseph E.","family":"Grossman","sequence":"additional","affiliation":[{"name":"13Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3285-365X","authenticated-orcid":true,"given":"Xin","family":"Huang","sequence":"additional","affiliation":[{"name":"14Pfizer Oncology, San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meggan","family":"Tammaro","sequence":"additional","affiliation":[{"name":"14Pfizer Oncology, San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8570-1401","authenticated-orcid":true,"given":"Jean-Fran\u00e7ois","family":"Martini","sequence":"additional","affiliation":[{"name":"14Pfizer Oncology, San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanke","family":"Yu","sequence":"additional","affiliation":[{"name":"14Pfizer Oncology, San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Kern","sequence":"additional","affiliation":[{"name":"14Pfizer Oncology, San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Macarulla","sequence":"additional","affiliation":[{"name":"15Gastrointestinal Cancer Unit, Vall d\u00b4Hebr\u00f3n University Hospital and Vall d\u00b4Hebr\u00f3n Institute of Oncology (VHIO), IOB Quir\u00f3n, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2022,11,2]]},"reference":[{"key":"2023032313595206300_","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1200\/JCO.2016.67.1412","article-title":"Metastatic pancreatic cancer: American Society of Clinical Oncology clinical practice guideline","volume":"34","author":"Sohal","year":"2016","journal-title":"J Clin Oncol"},{"key":"2023032313595206300_","doi-asserted-by":"crossref","first-page":"131","DOI":"10.12688\/f1000research.21981.1","article-title":"Recent advances in the treatment of pancreatic cancer","volume":"9","author":"Roth","year":"2020","journal-title":"F1000Res"},{"key":"2023032313595206300_","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"2023032313595206300_","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1002\/ijc.31751","article-title":"Results from the prospective German TPK clinical cohort study: treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma","volume":"144","author":"Hegewisch-Becker","year":"2019","journal-title":"Int J Cancer"},{"key":"2023032313595206300_","article-title":"Full prescribing information","author":"Lynparza\u00ae (olaparib)","year":"2019"},{"key":"2023032313595206300_","unstructured":"US Food and Drug Administration. FDA approves olaparib for gBRCAm metastatic pancreatic adenocarcinoma. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-olaparib-gbrcam-metastatic-pancreatic-adenocarcinoma."},{"key":"2023032313595206300_","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.4_suppl.637","article-title":"Randomized phase III study of FOLFOX alone and with pegilodecakin as second-line therapy in patients with metastatic pancreatic cancer (SEQUOIA)","volume":"38","author":"Hecht","year":"2020","journal-title":"J Clin Oncol"},{"key":"2023032313595206300_","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.4540","article-title":"Phase Ib\/II open-label, randomized evaluation of 2L atezolizumab (atezo) + PEGPH20 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC)","volume":"38","author":"Ko","year":"2020","journal-title":"J Clin Oncol"},{"key":"2023032313595206300_","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12943-020-01151-3","article-title":"Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma","volume":"19","author":"Fan","year":"2020","journal-title":"Mol Cancer"},{"key":"2023032313595206300_","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature16965","article-title":"Genomic analyses identify molecular subtypes of pancreatic cancer","volume":"531","author":"Bailey","year":"2016","journal-title":"Nature"},{"key":"2023032313595206300_","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1126\/science.1164368","article-title":"Core signaling pathways in human pancreatic cancers revealed by global genomic analyses","volume":"321","author":"Jones","year":"2008","journal-title":"Science"},{"key":"2023032313595206300_","doi-asserted-by":"crossref","first-page":"5320","DOI":"10.1158\/1078-0432.CCR-13-0259","article-title":"The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma","volume":"19","author":"Sheppard","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2023032313595206300_","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1177\/1947601913478972","article-title":"CDK4: a key player in the cell cycle, development, and cancer","volume":"3","author":"Baker","year":"2012","journal-title":"Genes Cancer"},{"key":"2023032313595206300_","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/gb4184","article-title":"Cyclin-dependent kinases","volume":"15","author":"Malumbres","year":"2014","journal-title":"Genome Biol"},{"key":"2023032313595206300_","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","article-title":"Overall survival with palbociclib and fulvestrant in advanced breast cancer","volume":"379","author":"Turner","year":"2018","journal-title":"N Engl J Med"},{"key":"2023032313595206300_","article-title":"Full Prescribing Information, Pfizer Inc","author":"IBRANCE\u00ae (palbociclib)","year":"2019"},{"key":"2023032313595206300_","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1136\/gutjnl-2017-315144","article-title":"Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer","volume":"67","author":"Chou","year":"2018","journal-title":"Gut"},{"key":"2023032313595206300_","doi-asserted-by":"crossref","first-page":"6512","DOI":"10.18632\/oncotarget.2270","article-title":"CDK4\/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer","volume":"5","author":"Franco","year":"2014","journal-title":"Oncotarget"},{"key":"2023032313595206300_","doi-asserted-by":"crossref","first-page":"15788","DOI":"10.18632\/oncotarget.3819","article-title":"Selective impact of CDK4\/6 suppression on patient-derived models of pancreatic cancer","volume":"6","author":"Witkiewicz","year":"2015","journal-title":"Oncotarget"},{"key":"2023032313595206300_","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1177\/1740774510382799","article-title":"A modified toxicity probability interval method for dose-finding trials","volume":"7","author":"Ji","year":"2010","journal-title":"Clin Trials"},{"key":"2023032313595206300_","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"2023032313595206300_","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1158\/1078-0432.CCR-06-0113","article-title":"An in vivo platform for translational drug development in pancreatic cancer","volume":"12","author":"Rubio-Viqueira","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2023032313595206300_","doi-asserted-by":"crossref","first-page":"598","DOI":"10.4161\/cbt.12.7.16475","article-title":"Cyclin-dependent kinase inhibitor dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models","volume":"12","author":"Feldmann","year":"2011","journal-title":"Cancer Biol Ther"},{"key":"2023032313595206300_","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1158\/1535-7163.MCT-15-0028","article-title":"Combined inhibition of cyclin-dependent kinases (dinaciclib) and AKT (MK-2206) blocks pancreatic tumor growth and metastases in patient-derived xenograft models","volume":"14","author":"Hu","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"2023032313595206300_","article-title":"Full Prescribing Information, Celgene Corporation","author":"Abraxane\u00ae (paclitaxel protein-bound particales for injectable suspension [albumin-bound])","year":"2013"},{"key":"2023032313595206300_","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00280-021-04263-9","article-title":"Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+\/HER2-advanced breast cancer in Chinese women","volume":"88","author":"Xu","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"key":"2023032313595206300_","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2011.36.5742","article-title":"Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I\/II trial","volume":"29","author":"Von Hoff","year":"2011","journal-title":"J Clin Oncol"},{"key":"2023032313595206300_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.19.00124","article-title":"Palbociclib in patients with pancreatic and biliary cancer with CDKN2A alterations: results from the Targeted Agent and Profiling Utilization Registry Study","volume":"3","author":"Al Baghdadi","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"2023032313595206300_","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ccell.2020.01.007","article-title":"CDK4\/6 inhibitors impair recovery from cytotoxic chemotherapy in pancreatic adenocarcinoma","volume":"37","author":"Salvador-Barbero","year":"2020","journal-title":"Cancer Cell"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-22-0072\/3207538\/crc-22-0072.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/2\/11\/1326\/3285024\/crc-22-0072.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/2\/11\/1326\/3285024\/crc-22-0072.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T20:41:43Z","timestamp":1727988103000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/2\/11\/1326\/710140\/A-Preclinical-and-Phase-Ib-Study-of-Palbociclib"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,2]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11,2]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-22-0072","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.22545087.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545090.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545072.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545072","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545075.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6550848","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545084","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545069.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6550848.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545075","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545081.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545090","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545081","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545069","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545084.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545066.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545087","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545066","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,2]]}}}